相关实验视频

Updated: May 28, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

针对口腔状细胞癌的ErbB和MUC1向的CAR-T细胞免疫疗法

Saffron E Summers^1,2, Vehid Salih², Andrew D Foey¹

¹School of Biomedical Sciences, Faculty of Health, University of Plymouth, Plymouth, United Kingdom.

Frontiers in dental medicine

|February 12, 2025

概括

化学抗原受体T (CAR-T) 细胞疗法对口腔状细胞癌 (OSCC) 有希望. 像向ErbB/MUC1和组合疗法等策略可以克服治疗这种固体瘤的挑战.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
生物技术是生物技术.

背景情况:

卡尔-T细胞治疗对B细胞恶性瘤有效,但在固体瘤中面临挑战,如头部和部状细胞癌 (HNSCC) 和口腔状细胞癌 (OSCC).
在HNSCC/OSCC的关键挑战包括识别一致表达的瘤相关抗原 (TAAs) 和克服免疫抑制性瘤微环境 (TME).

研究的目的:

审查CAR-T细胞的工程和代.
为了突出潜在的CAR-T目标 (ErbB,MUC1) 对于HNSCC/OSCC.
讨论提高CAR-T在固体瘤中的疗效的策略.

主要方法:

审查CAR-T细胞工程过程和代.
在HNSCC中对TAAs (ErbB,MUC1) 的分析.
探索组合疗法 (CAR-T与PD-L1等免疫检查点抑制剂).
研究先进的CAR-T设计 (双重定位,synNOTCH) 和TME定位策略.

主要成果:

针对ErbB和MUC1的CAR-T疗法显示出HNSCC/OSCC的潜力.
组合疗法,包括PD-L1抑制剂,可能会产生协同作用的抗瘤反应.
先进的CAR-T设计和TME准策略可以提高安全性和有效性.

结论:

在HNSCC/OSCC治疗中,CAR-T细胞疗法具有前景.
克服与TME相关的挑战和采用组合策略对于治疗成功至关重要.
对新的CAR-T设计和组合疗法的进一步研究是OSCC管理的必要条件.

关键词:

在CAR-T中,我们可以使用CAR-T.这是ErbBB的意思.在MUC1中,MUC1是MUC1.这是OSCCCC的OSCC.在PD-L1中.这就是TAMs.

更多相关视频

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...